Project Grant R01AI195954
Award Date 8/24/26
Completion Date 7/31/31
Dollars Obligated $756K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $327,727 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct longitudinal metabolomics research investigating the relationship between intestinal microbial metabolites and food allergy development in infants. The research leverages a prospective infant cohort with longitudinal biobanked samples and existing clinical metadata to...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $493,889 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of food-specific antibody induction in the gut. The research will elucidate how invariant natural killer T cells, type 2 conventional dendritic cells, and T follicular helper cells work in concert to promote production of food-specific immunoglobulin E antibodies, using a mouse model...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $530,480 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop intravenously administered acetalated dextran microparticles for treating multiple sclerosis. The recipient will conduct basic and translational research on biopolymeric acetalated dextran microparticles designed to target B cells in vivo and induce antigen-specific...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $251,324 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered organ transplants resistant to antibody-mediated rejection through synthetic biology platforms. The research focuses on designing signal-inducible, drug-controllable endopeptidases for localized antibody degradation within transplanted tissue. The award funds...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will evaluate the efficacy of coreceptor therapy using low-dose nondepleting anti-CD4 antibodies to induce de-differentiation of autoreactive T follicular helper cells (TFH) and promote their conversion into functional regulatory T cells (TREG) in the context of type 1...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $250,642 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to estimate the causal effect of early peanut introduction on the risk of peanut-induced food protein enterocolitis syndrome (FPIES). The research leverages existing electronic health record data and caregiver surveys from the IREACH trial, a randomized controlled trial conducted across 30 pediatric...
- The National Institute of Allergy and Infectious Diseases awarded a $1.444 million cooperative agreement to Icahn School of Medicine at Mount Sinai on May 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on immunologic mechanisms underlying peanut oral immunotherapy (OIT) and desensitization outcomes. The project, titled Immunologic Trajectories of Peanut Desensitization (INROADS), will investigate dynamic changes in circulating cellular...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $756,988 on August 14, 2026, for research on antibody-based approaches to limit parainfluenza virus type 3 (PIV3) infection and disease in human lung models. The project develops and evaluates monoclonal antibodies (MABs) as therapeutic interventions against PIV3, a significant cause of croup, bronchopneumonia, and respiratory illness in infants, immunocompromised individuals, and...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $790,085 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of T cell responses in alpha-gal syndrome sensitization triggered by Lone Star tick bites. The research examines why bites from Amblyomma americanum ticks induce immunoglobulin E responses to alpha-gal, a carbohydrate present in mammalian meat, causing delayed...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into phage-mediated reprogramming of the gut microbiome to suppress chronic inflammation in inflammatory bowel disease. The funded research, R21AI197116, engineers self-complementary non-replicative phage vectors to deliver therapeutic genetic modifications to existing...